Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab versus placebo after platinum-based chemotherapy and bevacizumab in late-relapse ovarian, fallopian tube, or peritoneal cancer
2015-005471-24Phase 3Completed
- Sponsor
- Arcagy-Gineco
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Atezolizumab arm with Placebo arm (2 arms). Primary endpoint: Progression-free survival (PFS1). Started Apr 2016; status: completed.
02
Drugs
atezolizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2015-005471-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005471-24.